The idea addresses a growing complication in oncology. Tumors can contain bacteria that are physically sheltered from conventional antibiotics and may alter the biology of surrounding cells. Some tumor-associated microbes can stimulate inflammatory signaling, interfere with immune surveillance or affect how drugs are metabolized. F. nucleatum, best known for its role in oral disease and colorectal cancer, has also been detected in breast tumors. Previous studies cited by the researchers have linked the bacterium to faster tumor growth and metastatic progression in breast cancer models. Intratumoral bacteria may also reduce chemotherapy efficacy by changing the local chemical environment or by promoting signals that help cancer cells survive. Yet most cancer drugs are designed to target tumor cells, while most antibiotics are administered systemically and are not optimized to reach bacteria embedded inside a solid tumor.

The new formulation uses a micelle, a nanoscopic structure assembled from molecules with both water-attracting and water-repelling components. In aqueous biological fluids, the hydrophobic portions cluster inward, forming a core that can solubilize poorly water-soluble compounds, while the hydrophilic polymer chains extend outward and stabilize the particle in water. Paclitaxel is highly hydrophobic and has limited water solubility, a property that complicates its formulation and distribution. By placing it inside the micelle core, POx can carry a high drug payload without relying on the same solvent systems used in some conventional formulations. The outer polymer layer helps the particles remain dispersed under physiological conditions, potentially allowing them to circulate and reach tumors through the abnormal blood vessels associated with solid cancers.

Metronidazole benzoate, the second cargo, is a derivative of metronidazole used to treat infections caused by anaerobic microorganisms. F. nucleatum is an anaerobic bacterium, meaning that it thrives in environments with little or no oxygen—conditions that can occur in poorly perfused regions of tumors. Once metronidazole-related compounds enter susceptible bacteria, their nitro group can be chemically reduced by microbial electron-transfer proteins. The resulting reactive intermediates damage DNA and other essential cellular components, ultimately killing the organism. The tumor environment therefore presents an unusual convergence of targets: paclitaxel disrupts the microtubule system required for cancer-cell division, while metronidazole benzoate is activated in anaerobic microbes. Packaging both agents in the same carrier could synchronize their delivery to a shared pathological site.

Paclitaxel works primarily by binding to tubulin, the protein subunit of microtubules. Rather than allowing microtubules to disassemble normally during cell division, the drug stabilizes them and prevents the dynamic rearrangements needed for chromosome segregation. Cells exposed to paclitaxel can become arrested in mitosis and eventually undergo cell death. Triple-negative breast cancer is a particularly important setting for this strategy because these tumors lack expression of estrogen receptors, progesterone receptors and HER2, limiting the usefulness of several targeted treatments. Chemotherapy remains a major component of treatment, but resistance and relapse are persistent problems. If bacteria in the tumor contribute to inflammatory or survival pathways, eliminating them at the same time as cancer cells could, in principle, remove one source of therapeutic resistance—although that possibility remains to be demonstrated in clinical studies.

The researchers report that the POx micelles containing paclitaxel and metronidazole benzoate formed monodisperse populations, meaning that the particles were relatively uniform in size rather than appearing as a mixture of widely different structures. Uniformity matters because particle size and morphology influence circulation, tissue penetration, drug release and uptake by cells. The formulation also showed high loading efficiency and loading capacity for the two compounds. Loading efficiency describes the fraction of the starting drug successfully incorporated into the carrier, whereas loading capacity refers to how much drug the final micelle material can hold. The authors further report that the co-loaded micelles remained stable under physiological conditions, an important requirement because premature disassembly in blood could release the drugs before they reach their intended destination.

The formulation was then tested against two triple-negative breast cancer cell lines in vitro. According to the study, the presence of both drugs in the POx carrier did not eliminate paclitaxel’s cytotoxic activity. In parallel experiments, the micelles displayed bactericidal activity against F. nucleatum, indicating that the antibacterial compound remained biologically available after incorporation into the polymeric structure. These experiments establish that co-encapsulation did not obviously neutralize either payload. They do not, however, prove that the particles selectively accumulate in human tumors, eradicate bacteria in patients or improve survival compared with standard paclitaxel and antibiotic treatment. Cell cultures and bacterial assays lack the complex blood flow, immune responses, extracellular matrix and oxygen gradients found in living tumors, so the results represent an early proof of feasibility rather than evidence of clinical effectiveness.

The team also examined tolerability in mice and found that the POx/PTX/MB micelles were well tolerated at pharmacologically relevant doses. That finding is encouraging because combining a cytotoxic drug with an antimicrobial agent can raise concerns about overlapping toxicity, altered metabolism and unintended effects on beneficial microorganisms. A nanocarrier could potentially change where and when each drug is released, but it could also introduce new variables, including accumulation in organs, interactions with immune cells and changes in pharmacokinetics. The study’s abstract does not report that the formulation cured tumors or reduced intratumoral bacterial burden in the animals; its animal result is specifically described as tolerability. Detailed questions about distribution, release rates, dose optimization and therapeutic benefit will therefore require further experiments in tumor-bearing models.

The choice of poly(2-oxazoline) reflects a broader effort to develop adaptable carriers for difficult-to-formulate medicines. POx polymers can be engineered by changing their chemical composition, block lengths and hydrophobicity, allowing researchers to tune micelle formation and drug interactions. Earlier work has shown that drugs can influence the shape of POx assemblies, causing transitions between spherical and elongated, worm-like structures. Such morphology can affect how particles move through the bloodstream and how they interact with cells. In the present study, the researchers used an amphiphilic triblock POx platform to accommodate two chemically distinct agents. That flexibility may be valuable for combination therapy, but it also makes manufacturing consistency essential: a future clinical product would need tightly controlled particle size, composition, drug ratio, stability and release behavior from batch to batch.

The work arrives as scientists increasingly investigate the tumor microbiome as a contributor to cancer biology rather than a passive collection of bystanders. Bacteria may reside between tumor cells, inside malignant cells or in specialized niches shaped by oxygen deprivation, immune suppression and altered nutrient availability. Targeting them could complement chemotherapy, immunotherapy or radiation, but indiscriminate antimicrobial treatment might also disrupt normal microbial communities and select for resistance. The researchers’ dual-purpose micelles offer a way to concentrate two established types of therapy in one nanoscale package, potentially reducing the need for separate delivery schedules and exposing bacteria and cancer cells to treatment within the same microenvironment. Before that promise can be tested in people, studies will need to determine whether F. nucleatum is present at clinically meaningful levels in specific breast tumors, whether its removal changes treatment response and whether the formulation improves efficacy without adding unacceptable toxicity. For now, the results suggest a provocative new direction: in some cancers, the most effective drug may need to target the tumor and its microscopic passengers together.

Subject of Research: Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate against triple-negative breast cancer cells and tumor-associated Fusobacterium nucleatum

Article Title: Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment

Article References: Holden, A., Hutsell, H., Palchak, L. et al. “Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment.” Biomedical Microdevices 28, 55 (2026). Original research article

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00834-w

Keywords: polymeric micelles, poly(2-oxazoline), paclitaxel, metronidazole benzoate, triple-negative breast cancer, tumor microbiome, Fusobacterium nucleatum, nanomedicine

Mitochondria, the powerhouse organelles of eukaryotic cells, have emerged as a compelling therapeutic target in oncology. Cancer cells demand enormous energy to sustain their rapid proliferation and altered metabolism, leading to changes in mitochondrial quantity and function. The aurB peptide operates by infiltrating the mitochondria of tumor cells and specifically targets ATP synthase, the enzyme complex critical for ATP production, thereby severing the energy supply crucial for tumor cell survival and growth.

The conceptual foundation for this therapy arises from a growing body of research highlighting the complex bacterial populations inhabiting tumor microenvironments. These bacteria have, for decades, been known to coexist with tumor cells, but only recently have scientists begun to exploit bacterial proteins as potential sources of anti-cancer agents. Previous work led by Tohru Yamada and his team investigated a bacterial cupredoxin protein capable of tumor suppression but found its efficacy hinged on the presence of functional p53, a tumor suppressor gene frequently mutated in cancers.

Acknowledging the limitations posed by p53 dependence, the researchers sought an alternative bacterial protein whose anti-cancer activity would transcend p53 status. Their attention turned to auracyanin, another member of the cupredoxin family containing copper and similarly involved in electron transport processes. By designing a peptide mimetic, aurB, based on auracyanin, they succeeded in generating an anti-cancer agent effective even in p53-inactive and hormone therapy-resistant prostate cancer models.

In the initial phase of their research, the team extensively profiled bacterial species within breast cancer tumor samples via DNA sequencing techniques. This approach revealed a predominance of auracyanin-containing bacteria, guiding the design and synthesis of aurB. Molecular characterization confirmed that aurB permeates cancer cells, localizing to mitochondria, and binds to ATP synthase. This interaction disrupts ATP synthesis, effectively depleting the intracellular energy stores indispensable for tumor cell viability.

To validate aurB’s therapeutic potential, the researchers evaluated the peptide’s performance in combination with radiation therapy in animal models bearing prostate tumors resistant to conventional hormone therapies. The results were profound, showing significant tumor growth inhibition without apparent systemic toxicity or deleterious side effects. The peptide-radiation combination exhibited synergism, amplifying cancer cell kill rates beyond what either treatment achieved independently.

From a translational standpoint, this study offers hope for a new class of mitochondria-targeting peptide therapeutics, capable of overcoming resistance mechanisms associated with common oncogenic mutations such as those affecting p53. The patented aurB peptide is poised for progression into clinical trials, marking an exciting step toward novel treatments for difficult-to-treat cancers that currently have limited therapeutic options and poor prognoses.

The University of Illinois Chicago-led research not only highlights the therapeutic promise of bacterial protein-derived peptides but also underscores the untapped potential of the tumor microbiome as a reservoir for novel cancer drug discovery. The concept of mining bacterial proteins from tumor-resident microbiota could open transformative avenues in oncology, where reprogramming the tumor milieu through biologically inspired peptides might revolutionize standard cancer care.

UIC’s multidisciplinary team collaborated across departments, underscoring the importance of integrating biomedical engineering, surgery, and clinical medicine expertise to translate fundamental scientific insights into pragmatic, life-saving interventions. This collective effort paved the way for rigorous preclinical validation, setting a robust foundation for future human clinical evaluations.

Going forward, the research team plans to expand their explorations into the broader tumor microbiome, hypothesizing that auracyanin is but one of numerous bacterial proteins with untapped anti-cancer potential. Developing advanced screening methodologies to identify and engineer additional bacterial peptides could substantially enrich the cancer therapeutics landscape, providing personalized and precision-guided options based on tumor microbial signatures.

The implications of this research reach beyond prostate cancer, as mitochondria-targeted therapies may hold promise against a variety of malignancies characterized by metabolic dysregulation and therapy resistance. By exploiting pathogen-inspired molecules naturally evolved to modulate cellular energetics, scientists are ushering in a new era of precision oncology, combining molecular biology, microbiology, and bioengineering to devise sophisticated cancer therapies.

This pioneering approach exemplifies how scientific innovation leverages nature’s molecular diversity—particularly the longstanding, intimate relationship between microorganisms and tumors—to devise treatments that are both highly specific and biologically grounded. It heralds a paradigm shift toward therapies that do not merely attack tumors indiscriminately but strategically dismantle their energy infrastructure, rendering cancer cells vulnerable and curbing tumor progression.

Subject of Research: Development of a bacterial protein-derived peptide, aurB, for mitochondria-targeted anti-cancer therapy, specifically for radiation-combined treatment of prostate cancer.

Article Title: Bacterial Protein-Inspired Peptide AurB Potently Suppresses Tumor Growth by Targeting Mitochondrial ATP Synthase in Preclinical Prostate Cancer Models

News Publication Date: Information not specified

Web References: https://doi.org/10.1038/s41392-026-02703-7

Image Credits: Photo by Jenny Fontaine/UIC

Keywords: Bacteria, Cancer, Peptides, Tumor microenvironments, Mitochondria, ATP synthase, Prostate cancer, Radiation therapy, Tumor microbiome, Cupredoxin, Aurora cyanin, p53-independent therapy